Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(1):1-6
Low-Dose Naltrexone in Rheumatological Diseases
Authors Information

1Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil

2Unit of Rheumatology, Hospital Evangélico Mackenzie, Curitiba, PR, Brazil

References
  1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014;33:451–9. https://doi.org/10.1007/s10067-014-2517-2.
  2. Bruun KD, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Holsgaard-Larsen A, Christensen R, et al.  Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials 2021;22(1):804. https://doi.org/10.1186/s13063-021-05776-7.
  3. Tempel A, Kessler JA, Zukin RS. Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions. J Neurosci 1990;10(3):741–7. https://doi.org/10.1523/JNEUROSCI.10-03-00741.1990.
  4. Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 2007;321(2):544–52. https://doi.org/10.1124/jpet.106.118810.
  5. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007;21(2):131–46. https://doi.org/10.1016/j.bbi.2006.10.011.
  6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009;10(4):663-72. https://doi.org/10.1111/j.1526-4637.2009.00613.x.
  7. Parkitny L, Younger J. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia. Biomedicines 2017;5(2):16. https://doi.org/10.3390/biomedicines5020016.
  8. Siembida J, Johnson B. Depression in fibromyalgia patients may require low-dose naltrexone to respond: A case report. Cureus 2022;14(2). https://doi.org/10.7759/cureus.22677. eCollection 2022.
  9. Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev 2018;14(2):177-80. https://doi.org/10.2174/1573397113666170321120329.
  10. Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry 2021;12:593842. https://doi.org/10.3389/fpsyt.2021.593842. eCollection 2021.
  11. Oaks Z, Stage A, Middleton B, Faraone S, Johnson B. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med 2018; 26(144):197-206. PMID: 30695679.
  12. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 2013;65(2):529-38. https://doi.org/10.1002/art.37734.
  13. Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med 2020; 21(10):2253-61. https://doi.org/10.1093/pm/pnaa001.
  14. Zashin S. Sjogren's syndrome and clinical benefits of low-dose naltrexone therapy: Additional case reports. Cureus 2020;12(7):e8948. https://doi.org/10.7759/cureus.8948.
  15. Zashin S. Sjogren's Syndrome: Clinical benefits of low-dose naltrexone therapy. Cureus 2019;11(3):e4225. https://doi.org/10.7759/cureus.4225.
  16. Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone. Dermatol Ther 2018;31(6):e12720. https://doi.org/10.1111/dth.12720.
  17. Manudhane AP, Schrom KP, Ezaldein HH, Armile JA. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J 2019;25(6):13030/qt89b75552.
  18. Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011;2011:804296. https://doi.org/10.1155/2011/804296.
  19. Raknes G, Småbrekke L. Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One 2019;14(2):e0212460. https://doi.org/10.1371/journal.pone.0212460. eCollection 2019.
  20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. https://doi.org/10.1186/s13643-020-01542-z.
  21. Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, et al. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006; 48(9):1871-9. https://doi.org/10.1016/j.jacc.2006.07.036.
  22. Clauw DJ, Arnold LM, McCarberg BH. FibroCollaborative. The science of fibromyalgia. Mayo Clin Proc 2011;86(9):907–11. https://doi.org/10.4065/mcp.2011.0206.
  23. Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia? Curr Pharm Des 2006;12(1):17–22. PMID: 16454720.
  24. Xu N, Wang Y, Zhao S, Jiao T, Xue H, Shan F, Zhang N. Naltrexone (NTX) relieves inflammation in the collagen-induced- arthritis (CIA) rat models through regulating TLR4/NFκB signaling pathway. Int Immunopharmacol 2020 Feb;79:106056.
  25. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95(8):547-52. https://doi.org/10.1093/qjmed/95.8.547.
  26. Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol 2018;61:178-84. https://doi.org/10.1016/j.intimp.2018.05.020.